XML 69 R58.htm IDEA: XBRL DOCUMENT
v3.23.1

Commitments and Contingencies - Additional Information (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | 24 Months Ended
--- | --- | --- | --- | ---
Mar. 31, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2018 | Sep. 30, 2024
Vetex Medical Limited [Member] |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |
Cash paid |  |  |  | $ 39,900,000 |  |  |
Deferred consideration, contractual value |  |  |  | $ 3,500,000 |  |  |
Installment payment beginning period |  |  |  | 2024 |  |  |
Installment payment ending period |  |  |  | 2027 |  |  |
Contingent consideration, contractual value |  |  |  | $ 3,500,000 |  |  |
Contingency period ending year |  |  |  | 2027 |  |  |
Embolitech LLC [Member] |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |
Contingent payments upon achievement of regulatory milestones |  | $ 1,000,000.0 |  |  |  |  |
Installment payment period | 2024 |  |  |  |  |  |
CRO [Member] |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |
Contractual obligation remaining to be paid | $ 2,000,000 | 2,000,000 |  |  |  |  |
CRO [Member] | Minimum [Member] |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |
Gross contractual obligation | 37,000,000 | 37,000,000 |  |  |  |  |
CRO [Member] | Maximum [Member] |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |
Gross contractual obligation | 40,000,000 | 40,000,000 |  |  |  |  |
CRO [Member] | Maximum [Member] | CRO Pass-through Expenses [Member] |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |
Gross contractual obligation | $ 30,000,000 | $ 30,000,000 |  |  |  |  |
In Process Research and Development | Embolitech LLC [Member] |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |
Contingency period ending year |  | 2033 |  |  |  |  |
Payments to acquire in-process research and development |  | $ 1,000,000.0 | $ 500,000 | $ 1,000,000.0 | $ 1,000,000.0 | $ 5,000,000.0 |
In Process Research and Development | Embolitech LLC [Member] | Forecast [Member] |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |
Contractual obligation payable in fiscal 2022 through fiscal 2024 |  |  |  |  |  |  | $ 1,000,000.0

X
- Definition Contingency, ending period, for business combination or asset acquisition. + References No definition available. + Details
Name: | srdx_AcquisitionContingencyPeriodEndingYear
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Installment payment, beginning period, for business combination or asset acquisition. + References No definition available. + Details
Name: | srdx_AcquisitionInstallmentPaymentBeginningPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Installment payment, ending period, for business combination or asset acquisition. + References No definition available. + Details
Name: | srdx_AcquisitionInstallmentPaymentEndingPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisition contingency period ending year. + References No definition available. + Details
Name: | srdx_AssetAcquisitionContingencyPeriodEndingYear
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisition contingent payments upon achievement of regulatory milestones. + References No definition available. + Details
Name: | srdx_AssetAcquisitionContingentPaymentsUponAchievementOfRegulatoryMilestones
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset acquisition installment payment period. + References No definition available. + Details
Name: | srdx_AssetAcquisitionInstallmentPaymentPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gross, contractual value of cash consideration to be transferred at a future date, if contingencies are met, by the acquirer to the former owners of the acquiree in a business combination. + References No definition available. + Details
Name: | srdx_BusinessCombinationContingentConsiderationContractual
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gross, contractual value of cash consideration to be transferred at a future date by the acquirer to the former owners of the acquiree in a business combination. + References No definition available. + Details
Name: | srdx_BusinessCombinationDeferredConsiderationContractual
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | srdx_CommitmentsAndContingenciesLineItems
Namespace Prefix: | srdx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gross amount of contractual obligation, including the portion of the obligation satisfied to date. + References No definition available. + Details
Name: | srdx_GrossContractualObligation
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payments to acquire businesses gross. + References No definition available. + Details
Name: | srdx_UpfrontPaymentsToAcquireBusinessesGross
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Future cash outflow to pay for purchases of fixed assets that have occurred. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586 + Details
Name: | us-gaap_CapitalExpendituresIncurredButNotYetPaid
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=srdx_VetexMedicalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=srdx_EmbolitechLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=srdx_ClinicalResearchOrganizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srdx_CROPassThroughExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |